.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Moodys
McKesson
Julphar
Daiichi Sankyo
Cantor Fitzgerald
Fish and Richardson
Baxter
Federal Trade Commission
Colorcon

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205836

« Back to Dashboard
NDA 205836 describes BRIVIACT, which is a drug marketed by Ucb Inc and is included in three NDAs. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the BRIVIACT profile page.

The generic ingredient in BRIVIACT is brivaracetam. One supplier is listed for this compound. Additional details are available on the brivaracetam profile page.

Summary for NDA: 205836

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1

Pharmacology for NDA: 205836

Mechanism of ActionEpoxide Hydrolase Inhibitors

Suppliers and Packaging for NDA: 205836

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BRIVIACT
brivaracetam
 TABLET;ORAL 205836 NDA UCB, Inc. 50474-370 50474-370-66 1 BOTTLE in 1 CARTON (50474-370-66) > 60 TABLET, FILM COATED in 1 BOTTLE
BRIVIACT
brivaracetam
 TABLET;ORAL 205836 NDA UCB, Inc. 50474-470 50474-470-09 100 BLISTER PACK in 1 CARTON (50474-470-09) > 1 TABLET, FILM COATED in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:May 12, 2016TE:RLD:Yes
Regulatory Exclusivity Expiration:May 12, 2021
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:6,784,197Patent Expiration:Feb 21, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
Patent:6,911,461Patent Expiration:Feb 21, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Chubb
Express Scripts
Colorcon
QuintilesIMS
Covington
Cipla
Argus Health
Deloitte
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot